DK0720745T3 - Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker - Google Patents

Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker

Info

Publication number
DK0720745T3
DK0720745T3 DK94928653T DK94928653T DK0720745T3 DK 0720745 T3 DK0720745 T3 DK 0720745T3 DK 94928653 T DK94928653 T DK 94928653T DK 94928653 T DK94928653 T DK 94928653T DK 0720745 T3 DK0720745 T3 DK 0720745T3
Authority
DK
Denmark
Prior art keywords
body fluids
quantification
bpi
extracellular
extracellular bpi
Prior art date
Application number
DK94928653T
Other languages
Danish (da)
English (en)
Inventor
Stephen Fitzhugh Carroll
Mark Leslie White
Jeremy Kam-Kuen Ma
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/125,677 external-priority patent/US5466580A/en
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of DK0720745T3 publication Critical patent/DK0720745T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
DK94928653T 1993-09-22 1994-09-22 Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker DK0720745T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/125,677 US5466580A (en) 1993-09-22 1993-09-22 Method for quantifying BPI in body fluids
US08/175,276 US5466581A (en) 1993-09-22 1993-12-29 Method for quantifying BPI in body fluids
PCT/US1994/010793 WO1995008773A1 (fr) 1993-09-22 1994-09-22 Procede de quantification de la proteine bpi dans des fluides corporels

Publications (1)

Publication Number Publication Date
DK0720745T3 true DK0720745T3 (da) 1999-06-23

Family

ID=26823820

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94928653T DK0720745T3 (da) 1993-09-22 1994-09-22 Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker

Country Status (12)

Country Link
US (1) US5821064A (fr)
EP (1) EP0720745B1 (fr)
JP (2) JPH09503296A (fr)
CN (1) CN1133634A (fr)
AT (1) ATE173830T1 (fr)
AU (1) AU697356B2 (fr)
CA (1) CA2172243C (fr)
DE (1) DE69414871T2 (fr)
DK (1) DK0720745T3 (fr)
ES (1) ES2126151T3 (fr)
NZ (1) NZ274083A (fr)
WO (1) WO1995008773A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1997004008A1 (fr) * 1995-07-20 1997-02-06 Xoma Corporation Peptides antifongiques
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DE69703689T2 (de) 1996-05-10 2001-05-10 Xoma Technology Ltd., Berkeley Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
JP6651794B2 (ja) * 2015-11-05 2020-02-19 富士レビオ株式会社 心筋トロポニンi測定試薬及び方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245013A (en) * 1985-04-30 1993-09-14 Richard Ulevitch Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
EP0563222B1 (fr) * 1990-12-03 1998-02-25 New York University Fragments biologiquement actifs de proteines bactericides/accroissant la permeabilite
WO1993006228A1 (fr) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. Nouvelle forme de proteine fixatrice des liposaccharides
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
AU669723B2 (en) * 1992-05-19 1996-06-20 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性/浸透性増大タンパク質(Bactericidal/Permeability Increasing protein:BPI)及び界面活性剤を含有する医薬組成物
JPH08509703A (ja) * 1993-03-12 1996-10-15 ゾーマ コーポレイション 殺菌/透過性増加タンパク質産物の治療用途
CA2157925C (fr) * 1993-03-12 2000-06-06 Xoma Corporation Traitement de maladies mycobacteriennes par administration de produits proteiniques bactericides augmentant la permeabilite
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis

Also Published As

Publication number Publication date
CA2172243A1 (fr) 1995-03-30
DE69414871T2 (de) 1999-06-10
DE69414871D1 (de) 1999-01-07
WO1995008773A1 (fr) 1995-03-30
CN1133634A (zh) 1996-10-16
HK1014207A1 (en) 1999-09-24
ES2126151T3 (es) 1999-03-16
EP0720745B1 (fr) 1998-11-25
US5821064A (en) 1998-10-13
AU697356B2 (en) 1998-10-01
JP2003315334A (ja) 2003-11-06
JPH09503296A (ja) 1997-03-31
CA2172243C (fr) 2002-06-18
ATE173830T1 (de) 1998-12-15
NZ274083A (en) 1998-02-26
AU7801094A (en) 1995-04-10
EP0720745A1 (fr) 1996-07-10

Similar Documents

Publication Publication Date Title
ATE182216T1 (de) Verfahren zur quantifizierung von lbp in körperflüssigkeiten
NO973444L (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
DK1095278T3 (da) Differentialdiagnose af neurodegeneration
ATE128183T1 (de) Peptide und antikörper, die die bindung von blutplättchen verhindern.
DK0682256T3 (da) Fremgangsmåde til en vivo-påvisning af collagennedbrydning
DK0720745T3 (da) Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
FR2664702B1 (fr) Procede de reduction d'interferences dans un dosage par fluorescence.
FI973561A7 (fi) Menetelmä ja yhdisteitä analysoitavien aineiden määrittämiseksi remane nssimittausten avulla ja mainittujen yhdisteiden käyttö
DE69606024D1 (de) Feststellung von antikörperproduktion
ATE223055T1 (de) Verfahren zur diagnose von chlamydia in einer biologischen extrazellulären flüssigkeit
ES2136272T3 (es) Procedimientos de ensayo y dispositivos para los mismos.
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE69618451D1 (de) Verfahren zur feststellung einer allergie
DK1297342T3 (da) Metode til diagnostisk bestemmelse af Alzheimer's sygdom på basis af holo-transcobalamin II
BR9510669A (pt) Método para determinar ou detectar danos em órgão de doador em seguida ao xenotransplante com base em analitos derivados do órgão do doador
DE69920981D1 (de) Knorpelresorptionsassays
FR2829576B1 (fr) Procede et dispositif d'isolement et/ou determination d'un analyte
DE69627352D1 (de) Verfahren zur identifizierung personen empfindlich für betahemolytischer streptococci-vermittelter neuropsychiatrischer krankheiten
CA2181815A1 (fr) Procede pour determiner la quantite de lbp dans des fluides corporels
KR970702928A (ko) 크립토콕쿠스증에 대해 위험이 큰 면역약화된 환자의 동정 방법(Method to identify immunocompromised patients at high risk for cryptococcosis)
ITRM930306A0 (it) Metodo per la evidenziazione di anticorpi anti-achr e corredo diagnostico per la sua realizzazione.